Eric Schadler
NPI 1225599897 · Dermatology Physician · Allendale, MI
Enrolled with Medicare as Practitioner - Dermatology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1225599897
- Entity type
- Individual
- Primary specialty
- Dermatology PhysicianAllopathic & Osteopathic Physicians
- Sex
- Male
- Sole proprietor
- No
- License
- 4301509654 (MI)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure28% of score
7 yrs in NPPES registry
- Profile completeness28% of score
100% of core fields populated
- Practice footprint17% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)28% of score
324 Medicare services, 2024 (ranked within specialty)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Destruction of Precancer Skin Growth, 2-14 Growths17003 | 66 | $6 |
| Biopsy of Related Skin Growth, First Growth11102 | 51 | $82 |
| New Patient Office Or Other Outpatient Visit With Low Level of Medical Decision Making, If Using Time, 30 Minutes Or More99203 | 49 | $102 |
| Biopsy of Related Skin Growth, Each Additional Growth11103 | 32 | $42 |
| Destruction of Precancer Skin Growth, 1 Growth17000 | 31 | $37 |
| New Patient Office Or Other Outpatient Visit With Moderate Level of Medical Decision Making, If Using Time, 45 Minutes Or More |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 10 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Triamcinolone Acetonide | 72 | 56 |
| Clobetasol Propionate | 50 | 32 |
| Ketoconazole | 50 | 33 |
| Clindamycin Phosphate | 23 | 13 |
| Hydrocortisone | 21 | 13 |
| Fluorouracil | 15 | 13 |
| Dupilumabbrand: Dupixent Pen | 14 | — |
| Prednisone |
Practice location
Mailing address
Registry dates
- Enumerated
- 2019-03-27
- Last updated
- 2023-08-31
- Certified
- 2023-08-31
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.